Beyond Biotech - the podcast from Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Episodes
182 episodes
Building a smart oncology pipeline with Cumulus Oncology
Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh. With over 25 years of expertise in oncology drug development, Clare has built a r...
•
Episode 182
•
34:42
Top 5 trends that will drive biopharma in the next decade with Tim Opler
Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acq...
•
Episode 181
•
36:25
Labiotech's 15 biopharma companies to watch in 2026
Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech player...
•
Episode 180
•
41:28
M Ventures: pharma CVC and biotech innovation in 2026
Welcome to our first episode for 2026.Today, we're joined by Hakan Goker, Managing Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biote...
•
Episode 179
•
35:43
Johnson & Johnson’s hematology portfolio: breakthroughs to watch
Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker.Today, though, I...
•
Episode 178
•
34:25
Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach
In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. Martin grew up just down the road from the company’s h...
•
Episode 177
•
38:47
Cracking Cancer’s Code: Transforming Research with Novel Cancer Models
Cancer is one of the biggest health challenges worldwide. While progress has been made, millions of patients are still in need of new treatment options that better address the complexities of their disease.BeOne Medicines is creating the...
•
Episode 176
•
29:47
Curing cancer: Daiichi Sankyo's ambitious ADC approach
Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.In today’s episode I’m joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at D...
•
Episode 175
•
39:42
How to succeed at BIO-Europe: DISCO Pharma takes us behind the scenes
Two weeks ago, the biopharma industry gathered in Vienna, Austria, for BIO-Europe. Tens of thousands of one-on-one meetings were organized between innovators and out-licensors with top pharma companies and venture capitalists eager to partner a...
•
Episode 174
•
28:23
Meet Fusix Biotech: 2025 BIO-Europe Startup Spotlight champion revolutionizing oncology
Last week saw more than 5,900 people from 3,200 companies gather in Vienna, Austria, for the continent’s largest biopharma partnering conference, BIO-Europe. Over three days the world’s top ph...
•
Episode 173
•
32:42
Next‑generation UTI diagnostics: delivering results in just 35 minutes
Urinary Tract infections, or UTIs, affect millions worldwide, driving sepsis, antibiotic overuse, and microbial resistance. Current diagnostics rely on either slow lab cultures or unreliable dipsticks, and often lead to delayed or unnecessary t...
•
Episode 172
•
39:22
How AI Is revolutionizing synthetic biology and biomanufacturing
Today, I’m joined by Héctor García Martín, a Staff Scientist at Lawrence Berkeley National Laboratory. A pioneer in metabolic engineering and computational biology, Héctor has spent over a decade decoding microbial systems, everything from term...
•
Episode 171
•
38:27
Pichia pastoris: the microbial protein expression platform you’re probably underestimating
Today we’re diving into the world of expression systems with Iskandar Dib, of Validogen and we’ll explore the remarkable potential of Pichia pastoris, a methylotrophic yeast that’s revolutionizin...
•
Episode 170
•
36:02
Biotech royalty deals on the rise and here to stay
In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx. HCRx are pioneers in royalty-based financing, with a thirty year track record in biopharma investing. Clarke has led more than 60 royalty acq...
•
Episode 169
•
51:18
Contraline's ADAM in the clinic: towards a new era of male contraception?
When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female con...
•
Episode 168
•
40:33
Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play
Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people,...
•
Episode 167
•
44:49
What’s next in immunology & inflammation R&D: The trends to watch
Immunology and inflammation are hot topics in biotech and biopharma, and innovations are emerging that can change the game for patients suffering from autoimmune, gastrointestinal, and metabolic disease. For top pharma companies, identifying th...
•
Episode 166
•
51:25
BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year
Partnering conferences are where many deals in the biotech industry get made. With investors and top pharma companies on hand to meet with founders, learn about new science, and put money on the table for promising biotech, it’s little wonder t...
•
Episode 165
•
44:54
AION Labs is building innovative biotechs with top pharma partners in Israel
How can you guarantee that top pharma will be interested in investing in your biotech startup? How can you be sure that the target you are focused on will be attractive to industry partners? And can AI help drive this interest and deliver these...
•
Episode 164
•
42:09
Navigating the biotech development journey from first steps to global scale with Lonza
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. They work alongside a broad range of customers – from emerging biotechs to top global pharmaceutical...
•
Episode 163
•
50:40
A Finnish biotech is making progress on Parkinson's disease with support from The Michael J. Fox Foundation
Parkinsons disease impacts some 10 million people worldwide and current approaches to treating the condition almost exclusively focus on addressing symptoms – there is, as of yet, no cure. One Finnish biotech, however, is not focused on allevia...
•
Episode 162
•
38:02
How RNAi is expanding from a therapy of choice for rare disease into treating common conditions
RNAi has changed the way that rare diseases are treated - is it about to do the same for more common conditions?Alnylam was the very first company to translate RNAi from Nobel Prize winning science into a commercially scalable pla...
•
Episode 161
•
48:01
Are next-generation psychedelics the way forward for addressing treatment resistant depression?
Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is ...
•
Episode 160
•
49:07
Day One DNA: How and why the UK is betting on whole genome sequencing for every newborn
The UK is preparing to change the game for healthcare - but why, how, and what will it cost?Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country’s 10 Year Health ...
•
Episode 159
•
49:57
Meatly's innovative cultivated meat is already delighting pets, are humans next?
Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too?Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, ...
•
Episode 158
•
38:45